TB/HIV Working Group

If you have TB/HIV Operational research study results you would like to share please tell us about it in one paragraph. Contact us at: tbhiv@who.int

CREATE - Read more

TB/HIV Research Priorities

TB/HIV research aims to better understanding the magnitude and burden of TB in HIV prevalent settings, to accelerating universal and effective implementation of collaborative TB/HIV activities, and to preventing unnecessary morbidity and mortality due to TB among people living with HIV. It embraces many aspects of research, from clinical to operational research and development of new technologies.

TB/HIV research should be made a priority by both HIV and TB research establishments and their funding agencies. Knowledge gaps in preventing, diagnosing and treating childhood TB/HIV co-infection or drug-resistant TB among people living with HIV are just some examples of the unmet research needs. Researchers, funding bodies and national governments should commit without any further delay to address gaps and priorities in TB/HIV research.

The Secretariat in collaboration with other partners organizes meetings with HIV and TB researchers to raise the profile of HIV/TB research. It has also initiated the process to define and revise the priorities for HIV/TB research.

TB/HIV at CROI 2009

The Stop TB Department of WHO in collaboration with the Consortium to Respond Effectively to the AIDS/TB Epidemic (CREATE) organized a meeting affiliated with the 16th Conference on Retroviruses and Opportunistic Infections (CROI 2009) in Montreal, Canada. This is the third in a series of meetings organized since 2007.

The meetings have successfully raised the profile of HIV/TB among HIV researchers in particular by sharing data from ongoing studies, identifying research gaps and stimulating further HIV/TB research. The main objective of the meeting at CROI 2009 was to promote high level scientific interchange of ideas and research priorities to have a better understanding of the magnitude and burden of TB (including drug resistant strains) especially in HIV prevalent settings.

Read the presentations made at the meeting

PK and Drug Interactions in a Changing World: New Drugs for TB and New Regimens for TB-HIV Co-infection by Charles Flexner, MD, Johns Hopkins University

Treatment of Extensively Drug Resistant Tuberculosis Among Patients with HIV Infection in South Africa by Max O'Donnell , Nesri Padayatchi, Iqubal Master, Garth Osburn, Robert Horsburgh

Sensitivity, specificity and predictive values of symptoms to detect tuberculosis in the ZAMSTAR community based prevalence studies by Peter Godfrey-Faussett and Helen Ayles, London School of Hygiene and Tropical Medicine, UK

TB/HIV research priorities in resource-limited settings
Report of an expert consultation
14-15 February 2005, Geneva, Switzerland